Clinical Trial Search

Primary: Performance of the PureWick System in Adolescents After HCP Placement and Self-placement — 90.40; 93.09; 87.15; 90.41 Percentage of urine captured

Primary: Change in Perceived Stress [Perceived Stress Scale (PSS)] — 26.33; 25.26; 22.01; 24.67 score on a scale — p=<.001

Primary: Mean Change From Baseline to 52 Weeks in Body Mass Index (BMI) for All Participants — 3.64; 2.83 kilograms per meter squared (kg/m^2) — p=0.150

Primary: Number of Participants With Cotinine-confirmed 7-day Point Prevalence Abstinence at the End of Treatment — 4; 4 Participants

Primary: Transition Readiness Assessment Questionnaire (TRAQ) Score — 2.77; 2.95; 3.80; 3.92 units on a scale

Primary: Change in Brain Response From Baseline to 2-weeks Post High UPF or 2 Weeks no UPF Diet — 0.02; 0.13 arbitrary units

Primary: Change From Baseline in Youth Executive Function (Behavioral EF) at 8 Weeks (Z-score) — 0.02; -0.02 z-score

Primary: 4-Week Continuous Abstinence Rate: Percentage of Participants Who Remained Abstinent From Week 9 Through Week 12 — 20.2; 27.2; 18.0 percentage of participants — p=0.6337

Primary: Enrollment and Recruitment Rate — 61; 62 Participants

Primary: Depressive Symptom Severity at Post-intervention — 8.39; 11.03 units on a scale — p=<0.001

Primary: Number of Participants With Uptake of 1 or More Health Services — 43; 33 Participants

Primary: For Part A, Pharmacokinetic (PK) Parameter: AUCtau of EVG — 31620.9 ng•h/mL

Primary: Linear Relationship Between HOMA-IR and Cognitive Function (R-squared) — 0.205; 0.299; 0.738; 0.0264 R-squared — p=0.162

Primary: Intraoperative Duration — 9.5 minutes

Primary: Children's Depression Rating Scale - Revised — 36.0; 37.5 score on a scale — p=0.76

Primary: The Primary Outcome Efficacy Measure: Rating of Aggression Against People and/or Property Scale (RAAPP) (Kemph et al 1993) — 1.7 units on a scale

Primary: Change From Baseline to Week 15 in Mean Pain Diary Score — -1.60; -0.94 Units on a scale — p=0.121

Primary: Appetite- Subjective — 9239.4; 7879.6; 6130.5; 8970.0 score on a scale*min

Primary: Number of Participants With Adolescent and Parent Reported Alcohol, Drug, Vaping and Tobacco Usage — 1; 1; 0; 425 Participants

Primary: Change in Positive and Negative Syndrome Scale (PANSS) Total Score — -26.7; -28.6; -21.2 points — p=0.05

Primary: Change in Severity of Adolescent Depressive Symptoms, Self-report — 8.14 T-score

Primary: The Safety of Dapivirine (25 mg) Administered Via a Silicone Vaginal Ring in HIV-uninfected Adolescent Females, When Inserted Once Every 4 Weeks During 24 Weeks of Study…

Primary: Number of Patients With Bleeding Events (Major and Minor) — 0 Participants

Primary: Number of Adolescents Who Self-reported HIV Testing and Counseling, Inclusive of the Adolescent Wellness Visit — 234; 86 Participants

Primary: Adverse Drug Reactions (ADRs) — 2; 1; 1; 1 Number of adverse drug reactions

Primary: Total Weight Loss — 11.35 kilograms

Primary: Change From Baseline in the Tablet Routine Questionaire (TRQ) "Past Month" Item at 24 Weeks — 21.5; 28.0 percent of medications not taken

Primary: Self-Injurious Thoughts and Behaviors Interview (SITBI) - Lifetime Episodes — 73.29; 0 episode count

Primary: Adverse Drug Reactions — 2 participants

Primary: 17-hydroxyprogesterone Response to ACTH — 2.4; 3.7; 3.1; 2.9 ng/mL